RECRUITING

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Talk to us

Conditions

Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Official Title

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Quick Facts

Study Start:2025-05-20
Study Completion:2032-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06876662

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Are currently enrolled and active in the originator study, 18001. A participant is considered active in the study if they are:
  2. * receiving study intervention
  3. * in the short-term follow-up period, or
  4. * in the long-term follow-up period.
  1. * Were a participant in the Phase 1b cohort of Study 18001.
  2. * Are pregnant or intend to become pregnant during the study or within 30 days of last dose of study treatment or intend to breastfeed during the study or within 1 week of the last dose of study treatment.

Contacts and Locations

Study Contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
CONTACT
3176154559
clinical_inquiry_hub@lilly.com

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
STUDY_DIRECTOR
Eli Lilly and Company

Study Locations (Sites)

Sylvester Comprehensive Cancer Center
Miami, Florida, 33136-1002
United States
Florida Cancer Specialists
Sarasota, Florida, 34232-6422
United States
The Emory Clinic
Atlanta, Georgia, 30322-1013
United States
Northwestern University
Chicago, Illinois, 60611-3013
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Mayo Clinic- Minnesota
Rochester, Minnesota, 55905
United States
University Of Nebraska Medical Center
Omaha, Nebraska, 69198
United States
Cayuga Cancer Center
Ithaca, New York, 14850
United States
Northwell Health
Lake Success, New York, 11042-1118
United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, 10065-6007
United States
Duke University Medical Center
Durham, North Carolina, 27710-4000
United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210-1063
United States
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104
United States
Tennessee Oncology
Nashville, Tennessee, 37203-2659
United States
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4000
United States
Swedish Cancer Institute
Seattle, Washington, 98104-3588
United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226-3548
United States

Collaborators and Investigators

Sponsor: Eli Lilly and Company

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-20
Study Completion Date2032-12

Study Record Updates

Study Start Date2025-05-20
Study Completion Date2032-12

Terms related to this study

Additional Relevant MeSH Terms

  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma